Partial Thromboplastin Time
"Partial Thromboplastin Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
| Descriptor ID |
D010314
|
| MeSH Number(s) |
E01.370.225.625.115.600 E05.200.625.115.600 G09.188.660
|
| Concept/Terms |
Kaolin-Cephalin Coagulation Time- Kaolin-Cephalin Coagulation Time
- Coagulation Time, Kaolin-Cephalin
- Kaolin Cephalin Coagulation Time
- Coagulation Time, Cephalin-Kaolin
- Coagulation Time, Cephalin Kaolin
- Cephalin-Kaolin Coagulation Time
- Cephalin Kaolin Coagulation Time
|
Below are MeSH descriptors whose meaning is more general than "Partial Thromboplastin Time".
Below are MeSH descriptors whose meaning is more specific than "Partial Thromboplastin Time".
This graph shows the total number of publications written about "Partial Thromboplastin Time" by people in this website by year, and whether "Partial Thromboplastin Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 2 | 15 | 17 |
| 2018 | 0 | 12 | 12 |
| 2019 | 1 | 8 | 9 |
| 2020 | 2 | 14 | 16 |
| 2021 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.
-
Biomarkers of Coagulation and Inflammation in COVID-19-Associated Ischemic Stroke. Stroke. 2021 11; 52(11):e706-e709.
-
Severe acquired haemophilia associated with asymptomatic SARS-CoV-2 infection. BMJ Case Rep. 2021 Jul 20; 14(7).
-
Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K. Diabetes Res Clin Pract. 2021 Aug; 178:108955.
-
COVID-19-related laboratory coagulation findings. Int J Lab Hematol. 2021 Jul; 43 Suppl 1:36-42.
-
Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. PLoS One. 2021; 16(6):e0252939.
-
Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):290-293.
-
Changes of coagulation function and risk of stroke in patients with COVID-19. Brain Behav. 2021 06; 11(6):e02185.
-
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy. Thromb Res. 2021 07; 203:1-4.
-
Comparison of clinical features on admission between coronavirus disease 2019 and influenza a among children: a retrospective study in China. BMC Infect Dis. 2021 Apr 17; 21(1):365.
-
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. Int J Lab Hematol. 2021 Dec; 43(6):1284-1290.